The performance of a polymerase chain reaction-based point-of-care assay, the cobas Strep A Nucleic Acid Test for use on the cobas Liat System (cobas Liat Strep A assay), for the detection of group A Streptococcus bacteria was evaluated in primary care settings. Throat swab specimens from 427 patients were tested with the cobas Liat Strep A assay and a rapid antigen detection test (RADT) by existing medical staff at 5 primary care clinics, and results were compared with bacterial culture. The cobas Liat Strep A assay demonstrated equivalent sensitivity (97.7%) and specificity (93.3%) to reference culture with a 15-minute turnaround time. In comparison to RADTs, the cobas Liat Strep A assay showed improved sensitivity (97.7% Liat vs 84.5% RADT). The Clinical Laboratory Improvement Amendments-waived cobas Liat Strep A assay demonstrated the ease of use and improved turnaround time of RADTs along with the sensitivity of culture.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1177/0009922816684602 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Burden of RSV infections among young children in primary care: a prospective cohort study in five European countries (2021-23).
Lancet Respir Med
January 2025
Netherlands Institute for Health Services Research, Utrecht, Netherlands. Electronic address:
Background: The majority of respiratory syncytial virus (RSV) infections in young children are managed in primary care, however, the disease burden in this setting remains poorly defined.
Methods: We did a prospective cohort study in primary care settings in Belgium, Italy, Spain, the Netherlands, and the UK during the RSV seasons of 2020-21 (UK only; from Jan 1, 2021), 2021-22, and 2022-23. Children aged younger than 5 years presenting to their general practitioner or primary care paediatrician with symptoms of an acute respiratory tract infection were eligible for RSV testing.
Evaluation of cobas® Liat® Cdiff, STANDARD™ M10 C. difficile and Xpert® C. difficile BT assays for rapid detection of toxigenic Clostridioides difficile.
J Microbiol Methods
November 2024
HUS Diagnostic Center, Clinical Microbiology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland. Electronic address:
We evaluated the analytical performance of three commercial molecular assays for rapid detection of Clostridioides difficile toxin B in stool samples. The results were compared with results from the BD MAX™ Cdiff assay. We analyzed forty negative and thirty-two positive stool samples with three rapid assays: Roche cobas® Liat® Cdiff, SD Biosensor STANDARD™ M10 C.
View Article and Find Full Text PDFAssessment of DNA/RNA Defend Pro: An Inactivating Sample Collection Buffer for Enhanced Stability, Extraction-Free PCR, and Rapid Antigen Testing of Nasopharyngeal Swab Samples.
Int J Mol Sci
August 2024
InActiv Blue, Industriepark Oost 2A, 8730 Beernem, Belgium.
Article Synopsis
- The study evaluated the DNA/RNA Defend Pro (DRDP) collection buffer for its ability to inactivate and stabilize patient samples, while assessing its effectiveness for extraction-free PCR and quick antigen testing.
- Out of 95 nasopharyngeal swab samples tested for various viruses, the results confirmed the presence of viral targets, showing that DRDP maintained sample stability and compatibility with testing methods including direct RT-qPCR.
- DRDP demonstrated excellent RNA stability for key viruses over a week at various temperatures, making it a reliable option for enhancing diagnostic efficiency in challenging testing environments.
Clinical performance of the Roche Cobas Liat SARS-CoV-2 & influenza A/B assay: A systematic review and meta-analysis.
J Clin Virol
October 2024
Department of Laboratory Medicine, Hallym University Kangnam Sacred Heart Hospital, Hallym University College of Medicine, Seoul, South Korea. Electronic address:
Respiratory tract infections caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and influenza viruses are persistent and critical. The Cobas Liat SARS-CoV-2 & influenza A/B assay (Multiplex Liat), the FDA-authorized point-of-care reverse transcriptase polymerase chain reaction (RT-PCR) assay, has a turnaround time of 20 min and high accuracy. This study evaluates the pooled performance of this assay to provide practical information.
View Article and Find Full Text PDFHeparin-mediated PCR interference in SARS-CoV-2 assays and subsequent reversal with heparinase I.
J Virol Methods
June 2024
Northern Pathology Victoria, Northern Health, Epping, VIC, Australia; NorthErn Clinical diagnostics and ThrombovAscular Research (NECTAR) Centre, Northern Health, Epping, VIC, Australia; Department of Medicine - Northern Health, University of Melbourne, Epping, VIC, Australia.
Heparin is postulated to block the interaction of SARS-CoV-2 with highly glycosylated proteins which are critical for binding the angiotensin-converting enzyme 2 (ACE2), an essential mechanism for host-cell entry and viral replication. Intranasal heparin is under investigation for use as a SARS-CoV-2 preventative in the IntraNasal Heparin Trial (INHERIT, NCT05204550). Heparin directly interferes with real-time quantitative polymerase chain reaction (RT-qPCR), the gold standard for SARS-CoV-2 detection.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!